PF 5230907
Alternative Names: Factor Xa variant (IL16); FXa; FXaI16L; PF 907; PF-05230907; PF-5230907Latest Information Update: 30 Oct 2021
Price :
$50 *
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Blood coagulation factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cerebral haemorrhage
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Cerebral-haemorrhage in Canada (IV, Injection)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Cerebral-haemorrhage in Spain (IV, Injection)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Cerebral-haemorrhage in United Kingdom (IV, Injection)